Bafna Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE878I01022
NSEID: BAFNAPH
BSEID: 532989

INR

145.19

0.00 (0.00%)

BSENSE

Dec 04

BSE+NSE Vol: 28.3 k

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "145.19",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "145.19",
    "mcapval": "",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE878I01022",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "28.3 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amidst Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3749115",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3749115.png",
        "date": "2025-12-05 14:36:39",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure in recent trading sessions, with the stock registering a lower circuit and an absence of buyers in the queue. This distress selling signals a challenging phase for the company within the Pharmaceuticals & Biotechnology sector, as it underperforms both its sector and the broader market benchmarks."
      },
      {
        "title": "Why is Bafna Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bafna-pharma-fallingrising-3747363",
        "imagepath": "",
        "date": "2025-12-05 01:09:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Bafna Pharmaceuticals has experienced a downward trajectory over the past week, with the stock declining by 5.93%, significantly underperforming the Sensex, which fell by only 0.69% during the same period. The one-month performance further emphasises this trend, as the stock dropped 8.30% while the Sensex gained 1.70%. Despite these short-term setbacks, the stock has delivered impressive year-to-date returns of 84.02%, far outpacing the Sensex’s 10.10% gain. Over the last year, the stock has also outperformed the benchmark with a 77.65% increase compared to the Sensex’s 6.40% rise.</p>\n<p>However, the longer-term picture is more nuanced. Over three years, Bafna Pharmaceuticals has appreciated by 46.36%, slightly ahead of the Sensex’s 3..."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3744340",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3744340.png",
        "date": "2025-12-03 13:35:44",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure in recent sessions, with the stock registering consecutive declines and a notable absence of buyers today. The pharmaceutical company’s shares have underperformed the broader market and sector indices, signalling distress selling and heightened market caution."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3741826",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3741826.png",
        "date": "2025-12-02 13:20:46",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and an absence of buyers in the queue. This development signals distress selling and raises concerns about the stock's immediate market sentiment."
      },
      {
        "title": "How has been the historical performance of Bafna Pharma.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bafna-pharma-3739329",
        "imagepath": "",
        "date": "2025-12-01 23:26:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Bafna Pharma’s net sales have seen a significant contraction over the past seven years. From a peak exceeding ₹185 crores in the fiscal year ending March 2014, sales declined steadily to ₹43.36 crores by March 2019. This downward trend reflects a substantial reduction in the company’s core operating income, which also fell from ₹185.34 crores in 2014 to ₹43.36 crores in 2019. The company’s other operating income was negligible in recent years, except for a notable ₹41.11 crores in 2015, which temporarily bolstered total operating income.</p>\n<p>Cost management has been a persistent issue. Raw material costs and purchase of finished goods have fluctuated but remained substantial relative to sales, contributing to negative operating marg..."
      },
      {
        "title": "Bafna Pharmaceuticals Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-interest-3738625",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_buyers_3738625.png",
        "date": "2025-12-01 11:31:19",
        "description": "Bafna Pharmaceuticals has captured market attention with extraordinary buying momentum, registering an upper circuit with exclusively buy orders in the queue. This rare phenomenon signals robust investor enthusiasm and the potential for a sustained multi-day circuit scenario, underscoring the stock’s remarkable performance in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-intense-selling-pressure-amid-lower-circuit-lockdown-3733804",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3733804.png",
        "date": "2025-11-27 14:40:46",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and registering only sell orders in the queue. This distress selling signals a challenging phase for the company as it continues to underperform relative to the broader market and its sector peers."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3731172",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3731172.png",
        "date": "2025-11-26 10:40:50",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure, with the stock registering a decline of 1.98% today and exhibiting a persistent downtrend over the past week. The absence of buyers and a queue dominated solely by sell orders signal distress selling, raising concerns about the stock’s near-term momentum within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-intense-selling-pressure-amid-lower-circuit-lockdown-3729151",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3729151.png",
        "date": "2025-11-25 14:40:47",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock registering a lower circuit and an absence of buyers in the queue. This development follows a series of consecutive declines, signalling distress selling within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 254,
    "sid": "852453",
    "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "details": "Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 13, 2019.",
      "source": "NSE",
      "caption": "Bafna Pharmaceuticals Limited - Outcome of Board Meeting",
      "datetime": "14-Nov-2019"
    },
    {
      "details": " <table><tr><td>The Exchange had sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. </td></tr></table>",
      "source": "NSE",
      "caption": "Reply to Clarification- Financial results",
      "datetime": "27-Aug-2019"
    },
    {
      "details": " <table><tr><td>BAFNAPHARM: Members of the Exchange are hereby informed that the trading in Equity Shares of Bafna Pharmaceuticals Limited shall be suspended w.e.f. August 26, 2019 (i.e. closing hours of trading on August 23, 2019) on account of Reduction of Share Capital. </td></tr></table>",
      "source": "NSE",
      "caption": "Suspension of trading in equity shares",
      "datetime": "21-Aug-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bafna Pharmaceuticals Faces Intense Selling Pressure Amidst Consecutive Losses

2025-12-05 14:36:39

Bafna Pharmaceuticals has encountered significant selling pressure in recent trading sessions, with the stock registering a lower circuit and an absence of buyers in the queue. This distress selling signals a challenging phase for the company within the Pharmaceuticals & Biotechnology sector, as it underperforms both its sector and the broader market benchmarks.

Why is Bafna Pharma. falling/rising?

2025-12-05 01:09:37

Recent Price Movement and Market Context

Bafna Pharmaceuticals has experienced a downward trajectory over the past week, with the stock declining by 5.93%, significantly underperforming the Sensex, which fell by only 0.69% during the same period. The one-month performance further emphasises this trend, as the stock dropped 8.30% while the Sensex gained 1.70%. Despite these short-term setbacks, the stock has delivered impressive year-to-date returns of 84.02%, far outpacing the Sensex’s 10.10% gain. Over the last year, the stock has also outperformed the benchmark with a 77.65% increase compared to the Sensex’s 6.40% rise.

However, the longer-term picture is more nuanced. Over three years, Bafna Pharmaceuticals has appreciated by 46.36%, slightly ahead of the Sensex’s 3...

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-03 13:35:44

Bafna Pharmaceuticals has encountered significant selling pressure in recent sessions, with the stock registering consecutive declines and a notable absence of buyers today. The pharmaceutical company’s shares have underperformed the broader market and sector indices, signalling distress selling and heightened market caution.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit

2025-12-02 13:20:46

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and an absence of buyers in the queue. This development signals distress selling and raises concerns about the stock's immediate market sentiment.

How has been the historical performance of Bafna Pharma.?

2025-12-01 23:26:00

Revenue and Operating Performance Trends

Bafna Pharma’s net sales have seen a significant contraction over the past seven years. From a peak exceeding ₹185 crores in the fiscal year ending March 2014, sales declined steadily to ₹43.36 crores by March 2019. This downward trend reflects a substantial reduction in the company’s core operating income, which also fell from ₹185.34 crores in 2014 to ₹43.36 crores in 2019. The company’s other operating income was negligible in recent years, except for a notable ₹41.11 crores in 2015, which temporarily bolstered total operating income.

Cost management has been a persistent issue. Raw material costs and purchase of finished goods have fluctuated but remained substantial relative to sales, contributing to negative operating marg...

Bafna Pharmaceuticals Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit

2025-12-01 11:31:19

Bafna Pharmaceuticals has captured market attention with extraordinary buying momentum, registering an upper circuit with exclusively buy orders in the queue. This rare phenomenon signals robust investor enthusiasm and the potential for a sustained multi-day circuit scenario, underscoring the stock’s remarkable performance in the Pharmaceuticals & Biotechnology sector.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-27 14:40:46

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and registering only sell orders in the queue. This distress selling signals a challenging phase for the company as it continues to underperform relative to the broader market and its sector peers.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-26 10:40:50

Bafna Pharmaceuticals has encountered significant selling pressure, with the stock registering a decline of 1.98% today and exhibiting a persistent downtrend over the past week. The absence of buyers and a queue dominated solely by sell orders signal distress selling, raising concerns about the stock’s near-term momentum within the Pharmaceuticals & Biotechnology sector.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-25 14:40:47

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock registering a lower circuit and an absence of buyers in the queue. This development follows a series of consecutive declines, signalling distress selling within the Pharmaceuticals & Biotechnology sector.

View All News

Announcement

Bafna Pharmaceuticals Limited - Outcome of Board Meeting

14-Nov-2019 | Source : NSE

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 13, 2019.

Reply to Clarification- Financial results

27-Aug-2019 | Source : NSE

The Exchange had sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.

Suspension of trading in equity shares

21-Aug-2019 | Source : NSE

BAFNAPHARM: Members of the Exchange are hereby informed that the trading in Equity Shares of Bafna Pharmaceuticals Limited shall be suspended w.e.f. August 26, 2019 (i.e. closing hours of trading on August 23, 2019) on account of Reduction of Share Capital.